Here are the 10-Q quarterly reports from Protagenic Therapeutics (PTIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PTIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTIX filings page.
Protagenic Therapeutics, Inc. (PTIX) reported another loss-making quarter for the three months ended June 30, 2026, with a net loss of $963,616 and no revenue, compared with a net loss of $5,057,523 a year earlier. Total operating expenses were $961,247, down from $1,208,374, mainly due to lower research and development and legal costs after unwinding the Phytanix Bio merger. Other income and expense were near breakeven, versus heavy derivative and extinguishment charges in 2025.
Cash in bank declined to $565,985 from $1,509,178 at March 31, 2026, as operating activities used $944,298 in cash during the quarter and there were no investing or financing inflows. Total assets were $2.8 million, including $2.1 million of intangible assets tied to in‑process R&D and assembled workforce, and stockholders’ equity was $1.7 million.
The company discloses a working capital deficit of $362,743 at June 30, 2026 and an accumulated deficit of $4,993,245. Management states that existing cash is insufficient to fund operations for twelve months from issuance of the financial statements and that these conditions raise substantial doubt about PTIX’s ability to continue as a going concern. PTIX is exploring equity financing, partnerships for its lead program, royalty-based arrangements, and other strategic alternatives to improve liquidity.
Protagenic Therapeutics, Inc. (PTIX) reported a sharp swing to quarterly net income of $2.21M for the three months ended December 31, 2025, driven mainly by a non‑cash gain of $3.11M from the change in fair value of derivative liabilities. Core operations remained loss‑making, with an operating loss of $0.93M in the quarter and $4.38M for the nine‑month period.
Total assets rose to $4.43M at December 31, 2025, primarily from acquiring Phytanix Bio’s in‑process R&D and assembled workforce recorded as intangible assets of $2.09M. Liabilities increased to $6.82M, leaving a stockholders’ deficit of $2.39M despite new equity, warrant exercises and non‑cash gains.
Cash used in operations was $3.07M over nine months, offset by $0.94M of net cash from the Phytanix Bio acquisition and $4.41M from financing activities, including $3.95M from warrant exercises and $0.40M from common stock sales, ending with cash of $2.21M.
The company disclosed a working capital deficit of $4.52M and an accumulated deficit of $9.11M as of December 31, 2025, and stated that recurring losses and expected funding needs within 12 months raise substantial doubt about its ability to continue as a going concern. Management highlighted a restructuring plan approved on August 8, 2025 to move to a virtual model and focus on priority clinical programs, targeting about $8M in annualized operating expense reductions. The report also details a reverse merger with Phytanix Bio completed in May 2025, recorded as a reverse acquisition, and notes that an agreement to rescind and unwind this merger was reached on February 17, 2026.